T1	Participants 311 366	patients with clinical stage I/II Hodgkin lymphoma (HL)
T2	Participants 60 96	negative stage I/II Hodgkin lymphoma
T3	Participants 666 790	patients attaining a negative early PET scan after two cycles of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine)
T4	Participants 867 946	Patients age 15 to 70 years with untreated clinical stage I/II HL were eligible
T5	Participants 1279 1315	The analysis included 1,137 patients
T6	Participants 1317 1436	In the favorable subgroup, 85.8% had a negative early PET scan (standard arm, one event v experimental arm, nine events
T7	Participants 1439 1561	In the unfavorable subgroup, 74.8% had a negative early PET scan (standard arm, seven events v experimental arm, 16 events
